Oaktree Acquisition Corp. III Life Sciences Other 8-K Filing
Oaktree Acquisition Corp. III Life Sciences held an extraordinary general meeting where shareholders approved an amendment to extend the deadline for completing an initial business combination from October 25, 2026, to as late as May 25, 2027. Additionally, the company's Sponsor converted 4,798,758 Class B ordinary shares into Class A ordinary shares on a one-for-one basis.
Oaktree Acquisition Corp. III Life Sciences Shareholder Meeting
Oaktree Acquisition Corp. III Life Sciences has postponed its extraordinary general meeting from October 16, 2026, to October 23, 2026. The meeting was called to vote on a proposal to extend the deadline for the company to complete an initial business combination. The postponement is intended to allow more time for the solicitation of shareholder proxies.
Oaktree Acquisition Corp. III Life Sciences Other 8-K Filing
Oaktree Acquisition Corp. III Life Sciences announced preliminary redemption results ahead of its shareholder meeting to extend its business combination deadline, with 13,326,977 Class A shares tendered for redemption. Additionally, the company's sponsor intends to convert 4,798,758 Class B ordinary shares into Class A ordinary shares on a one-for-one basis prior to the extension's effectiveness.